Pfizer's mRNA flu vaccine hits primary goals in phase 3 trial, but secondary miss raises questions

Pfizer has capped off a landmark six weeks for the push to apply mRNA to influenza. Following a flurry of positive updates from Pfizer and chief mRNA rival Moderna, the Big Pharma has revealed a phase 3 trial of its mRNA flu candidate met both primary endpoints—but a secondary endpoint miss raises questions.